BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Prantera C, Rizzi M. 5-ASA in ulcerative colitis: Improving treatment compliance. World J Gastroenterol 2009; 15(35): 4353-4355 [PMID: 19764084 DOI: 10.3748/wjg.15.4353]
URL: https://www.wjgnet.com/1007-9327/full/v15/i35/4353.htm
Number Citing Articles
1
Gary R. Lichtenstein, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes. Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative ColitisInflammatory Bowel Diseases 2014; 20(8): 1399 doi: 10.1097/MIB.0000000000000076
2
El Bethel Lalthavel Hmar, Sujata Paul, Nayanmoni Boruah, Priyanka Sarkar, Sudarshana Borah, Hemanta Kumar Sharma. Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role?Current Pathobiology Reports 2021; 9(1): 9 doi: 10.1007/s40139-020-00218-6
3
Radan Keil, Martin Wasserbauer, Zdena Zádorová, Vladimír Kojecký, Štěpán Hlava, Jan Št’ovíček, Jakub Chudý, Markéta Roznětinská, Jiří Drábek, Nikola Kubišová, Jindra Lochmannová. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational studyScandinavian Journal of Gastroenterology 2018; 53(4): 459 doi: 10.1080/00365521.2018.1451915
4
Chien Nguyen, J. Mark Christensen, James W. Ayres. Novel mesalamine-loaded beads in tablets for delayed release of drug to the colonPharmaceutical Development and Technology 2012; 17(1): 73 doi: 10.3109/10837450.2010.516436
5
Jinyi Zhai, Julia Mantaj, Driton Vllasaliu. Ascorbyl Palmitate Hydrogel for Local, Intestinal Delivery of MacromoleculesPharmaceutics 2018; 10(4): 188 doi: 10.3390/pharmaceutics10040188
6
S. P. L. Travis, P. D. R. Higgins, T. Orchard, C. J. Van Der Woude, R. Panaccione, A. Bitton, C. O’Morain, J. Panés, A. Sturm, W. Reinisch, M. A. Kamm, G. D’Haens. Review article: defining remission in ulcerative colitisAlimentary Pharmacology & Therapeutics 2011; 34(2): 113 doi: 10.1111/j.1365-2036.2011.04701.x
7
P. Frei, G. Rogler. Topische Therapie bei chronisch-entzündlichen Darmerkrankungencoloproctology 2014; 36(5): 353 doi: 10.1007/s00053-014-0468-3
8
Michael Stephens, Michelle Gonzalez. Pediatric Inflammatory Bowel Disease2017; : 317 doi: 10.1007/978-3-319-49215-5_25
9
Tereza Bautzová, Miloslava Rabišková, Alf Lamprecht. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel diseaseDrug Development and Industrial Pharmacy 2011; 37(9): 1100 doi: 10.3109/03639045.2011.560156
10
Michael Stephens, Alisha M. Mavis. Pediatric Inflammatory Bowel Disease2013; : 281 doi: 10.1007/978-1-4614-5061-0_26
11
Yun-Chu Chen, Sheryhan F. Gad, Dhawal Chobisa, Yongzhe Li, Yoon Yeo. Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunitiesJournal of Controlled Release 2021; 330: 438 doi: 10.1016/j.jconrel.2020.12.025
12
Sidhartha R. Sinha, Linh P. Nguyen, Mohammed Inayathullah, Andrey Malkovskiy, Frezghi Habte, Jayakumar Rajadas, Aida Habtezion. A Thermo-Sensitive Delivery Platform for Topical Administration of Inflammatory Bowel Disease TherapiesGastroenterology 2015; 149(1): 52 doi: 10.1053/j.gastro.2015.04.002
13
Christopher S.J. Probert, Axel U. Dignass, Stefan Lindgren, Marco Oudkerk Pool, Philippe Marteau. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of lifeJournal of Crohn's and Colitis 2014; 8(3): 200 doi: 10.1016/j.crohns.2013.08.007
14
Dae-Seung Kim, Sung-Hee Kim, Ji-Ye Kee, Yo-Han Han, JinBong Park, Jeong-Geon Mun, Moon-Jung Joo, Yong-Deok Jeon, Su-Jin Kim, Sang-Hyun Park, Sung-Joo Park, Jae-Young Um, Seung-Heon Hong. Eclipta prostrataImproves DSS-Induced Colitis through Regulation of Inflammatory Response in Intestinal Epithelial CellsThe American Journal of Chinese Medicine 2017; 45(05): 1047 doi: 10.1142/S0192415X17500562
15
Bryan L Love, April D Miller. Extended-Release Mesalamine Granules for Ulcerative ColitisAnnals of Pharmacotherapy 2012; 46(11): 1529 doi: 10.1345/aph.1R171
16
P. Frei, G. Rogler. Topische Therapie bei chronisch-entzündlichen DarmerkrankungenDer Gastroenterologe 2013; 8(3): 197 doi: 10.1007/s11377-012-0724-4
17
F. Seibold, N. Fournier, C. Beglinger, C. Mottet, V. Pittet, G. Rogler. Topical therapy is underused in patients with ulcerative colitisJournal of Crohn's and Colitis 2014; 8(1): 56 doi: 10.1016/j.crohns.2013.03.005
18
Yan-cheng Dai, Zhi-peng Tang, Zhen-nan Wang, Ya-li Zhang, Xin-ying He. Influence of Shenqing Recipe on Morphology and Quantity of Colonic Interstitial Cells of Cajal in Trinitrobenzene Sulfonic Acid Induced Rat ColitisChinese Medical Sciences Journal 2011; 26(1): 43 doi: 10.1016/S1001-9294(11)60018-7
19
H. Ueyama, KI. Fu, K. Ogura, S. Murata, A. Miyazaki. Successful treatment for Cronkhite-Canada syndrome with endoscopic mucosal resection and salazosulfapyridineTechniques in Coloproctology 2014; 18(5): 503 doi: 10.1007/s10151-012-0863-0
20
Salam F. Zakko, Glenn L. Gordon, Uma Murthy, Shahriar Sedghi, Ronald Pruitt, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes, Gary R. Lichtenstein. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factorsPostgraduate Medicine 2016; 128(3): 273 doi: 10.1080/00325481.2016.1152876
21
Andreea Aprodu, Julia Mantaj, Bahijja Raimi-Abraham, Driton Vllasaliu. Evaluation of a Methylcellulose and Hyaluronic Acid Hydrogel as a Vehicle for Rectal Delivery of BiologicsPharmaceutics 2019; 11(3): 127 doi: 10.3390/pharmaceutics11030127
22
Michelle Gonzalez, Michael Stephens. Pediatric Inflammatory Bowel Disease2023; : 339 doi: 10.1007/978-3-031-14744-9_25